Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427936 | PMC |
http://dx.doi.org/10.1001/jamanetworkopen.2023.29006 | DOI Listing |
AAPS J
December 2024
Laboratory of Immunology, Office of Pharmaceutical Quality Research Division-IV, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.
Characterizing and mitigating factors that impact product immunogenicity can aid in risk assessment and/or managing risk following manufacturing changes. For follow-on products that have the same indication, patient population, and active product ingredient, the residual immunogenicity risk resides predominantly on differences in product and process related impurities. Characterizing differences in innate immune modulating impurities (IIRMI), which could act as adjuvants by activating local antigen presenting cells (APCs), can inform the immunogenicity risk assessment potentially reducing the need for clinical trials.
View Article and Find Full Text PDFAm J Obstet Gynecol MFM
December 2024
Faculty of Medicine, Department of Obstetrics and Gynecology, University of Malaya, Jalan Profesor Diraja Ungku Aziz, Kuala Lumpur, Malaysia. Electronic address:
Prenat Diagn
April 2024
Biomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota, USA.
Objectives: Thirty-five states, including Florida, now cover cell-free DNA (cfDNA) screening of fetuses for all pregnant patients enrolled in state public insurance programs. We interviewed Black and Hispanic obstetric patients at a safety net clinic in Florida shortly after the state rolled out cfDNA as a first-tier screening method for publicly insured patients.
Methods: Black and Hispanic patients receiving prenatal care from a prenatal or maternal fetal medicine clinic at a federally qualified health center in Jacksonville, FL were invited to participate in a qualitative interview in English or Spanish to explore experiences and perceptions of prenatal cfDNA screening.
JAMA Netw Open
August 2023
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts.
Ther Innov Regul Sci
September 2023
Haleon, 184 Liberty Corner Rd, Warren, NJ, 07059-6796, USA.
Objectives: This evaluation assesses the quantity, uniqueness, and innovative nature of the past 20 years of Rx-to-OTC (RTO) switches, where a current prescription (Rx) product is reclassified for over-the-counter (OTC) status. Broadening access to more OTC drugs with well-established safety and efficacy could help to reduce healthcare expenditure and address public health challenges.
Methods: The FDA-maintained RTO switch list website was accessed to generate the primary dataset.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!